Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2)
Carlos A. Morillo(Spanish National Centre for Cardiovascular Research), Girish M. Nair(Ottawa Heart Institute), Atul Verma(McGill University Health Centre), Jean Champagne(Université Laval), Heather Beresh(Population Health Research Institute), Laurence D. Sterns(Victoria Hospital), Andrea Natale(Texas Cardiac Arrhythmia), Stuart J. Connolly(Population Health Research Institute), Jeff S. Healey(Population Health Research Institute), Karl Heinz Kuck(Asklepios Klinik St. Georg)
Cited by 662
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
Subclinical Atrial Fibrillation and the Risk of Stroke
|New England Journal of Medicine|2012|2.1k
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Canadian Implantable Defibrillator Study (CIDS)
|Circulation|2000|1.6k